90874-34-3 Usage
Uses
Used in Pharmaceutical Synthesis:
3-BENZYLAZETIDINE is utilized as a key building block in the creation of pharmaceuticals, leveraging its distinctive structure to contribute to the development of new therapeutic agents. Its incorporation into drug molecules can enhance their efficacy and selectivity, making it an essential component in medicinal chemistry.
Used in Bioactive Molecule Development:
In the realm of bioactive molecules, 3-BENZYLAZETIDINE serves as a vital precursor, facilitating the synthesis of compounds with potential biological activity. Its unique reactivity allows for the generation of molecules that can interact with biological targets, thus offering new avenues for treating various diseases and conditions.
Used in Organic Chemistry Research:
3-BENZYLAZETIDINE is employed as a research tool in organic chemistry, where its properties are harnessed to explore novel reactions and mechanisms. Its presence in this field underscores its role in advancing the understanding of chemical processes and the creation of new synthetic methodologies.
Used in Medicinal Chemistry Research:
Within medicinal chemistry, 3-BENZYLAZETIDINE is applied as a versatile component in the design and synthesis of drug candidates. Its unique structural attributes and reactivity make it a valuable asset in the development of compounds with optimized pharmacological properties, such as potency, selectivity, and bioavailability.
Check Digit Verification of cas no
The CAS Registry Mumber 90874-34-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,0,8,7 and 4 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 90874-34:
(7*9)+(6*0)+(5*8)+(4*7)+(3*4)+(2*3)+(1*4)=153
153 % 10 = 3
So 90874-34-3 is a valid CAS Registry Number.
90874-34-3Relevant academic research and scientific papers
Catalytic Enantioselective Intermolecular Desymmetrization of Azetidines
Wang, Zhaobin,Sheong, Fu Kit,Sung, Herman H. Y.,Williams, Ian D.,Lin, Zhenyang,Sun, Jianwei
supporting information, p. 5895 - 5898 (2015/05/27)
The first catalytic asymmetric desymmetrization of azetidines is disclosed. Despite the low propensity of azetidine ring opening and challenging stereocontrol, smooth intermolecular reactions were realized with excellent efficiency and enantioselectivity.
AMINO-HETEROCYCLIC COMPOUNDS
-
Page/Page column 39, (2010/08/07)
The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, A, and n are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.
AZETIDINE-SUBSTITUTED PYRAZOLINES AS PAR-1 ANTAGONISTS
-
Page/Page column 55, (2008/06/13)
The invention relates to blood clotting, and especially to the use of azetidine-substituted pyrazolines as medicaments, novel azetidine-substituted pyrazolines, methods for the production thereof, and the use of the same for producing medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular diseases, preferably thromboembolic diseases.
